Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA). The product is part of the niche and small volume product portfolio with limited competition in the US market.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US$ 15 Mn. The product will be manufactured at the company's flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.
The company has 124 cumulative ANDA filings with USFDA of which 86 ANDAs have been approved and 38 are pending approval.
Triamcinolone Acetonide Ointment 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Shares of Strides Pharma Science Ltd was last trading in BSE at Rs.399.6 as compared to the previous close of Rs. 398.3. The total number of shares traded during the day was 172543 in over 2880 trades.
The stock hit an intraday high of Rs. 409.5 and intraday low of 397.4. The net turnover during the day was Rs. 69041548.